Placenta Accreta, Third TrimesterNCT07755709
Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
An observational study of Placenta Accreta, Third Trimester, run by Sohag University.
Trial summary
Primary Objective: To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta). To evaluate the diagnostic accuracy of the novel Ultrasound Scoring System in predicting the severity of Placenta Accreta Spectrum (PAS)… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Placenta Accreta, Third Trimester
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 4 Aug 2026to 1 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: Pregnant women aged 18 to 45 years. Gestational age ≥28 weeks at the time of enrollment. Diagnosed Placenta Previa with a history of: One or more previous cesarean sections Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).
Who may be able to join
- Pregnant women aged 18 to 45 years.
- Gestational age ≥28 weeks at the time of enrollment.
- Diagnosed Placenta Previa with a history of:
- One or more previous cesarean sections
- Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).
- Singleton pregnancy.
Who cannot join
- Women with multiple pregnancies (twins, triplets, etc.).
- Pregnancies complicated by acute medical conditions (e.g., heart failure, uncontrolled diabetes).
- Prior history of Blood diseases. (other than those related to pregnancy).
- Women who refuse to participate or withdraw consent during the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Novel Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
Primary Objective:
To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta). To evaluate the diagnostic accuracy of the novel Ultrasound Scoring System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).
Read more
Secondary Objective:
- To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).
- To assess the relationship between the novel ultrasound score and postoperative complications, such as:
- Requirement for hysterectomy
- Bladder or bowel injury
- Blood transfusion requirement
- ICU admission rates
- To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
Read the detailed description
Primary Objective:
- To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta).
- To evaluate the diagnostic accuracy of the novel Ultrasound Scoring
- System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).
Secondary Objective:
- To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).
- To assess the relationship between the novel ultrasound score and postoperative complications, such as:
- Requirement for hysterectomy
- Bladder or bowel injury
- Blood transfusion requirement
- ICU admission rates
- To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
- Conditions
- Placenta Accreta, Third Trimester
- Keywords
- placenta accreta
- Medical subject headings
- Placenta Accreta
What is being measured
The primary outcome is the main question the study is designed to answer.
degree of placental invasion and inability to conserve the uterus
Need for Hysterectomy: Determined by the degree of placental invasion and inability to conserve the uterus \&Histopathogy confirmation. Bladder Injury: Recorded if any injury occurs during the procedure.
Blood Transfusion Requirement: Amount of blood transfused intraoperatively.
ICU Admission: Postoperative ICU admission requirement due to hemorrhage or other complications.
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2026
- Study start4 Aug 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta Accreta, Third TrimesterStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Adel Khalifa, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07755709
- Sponsor's protocol ID
- Soh-Med-26-7-7MS
- Status last verified
- Aug 2026
- First submitted
- 4 Aug 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Novel Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
- ClinicalTrials.gov ID
- NCT07755709
- Acronym / sponsor ID
- Soh-Med-26-7-7MS
- Conditions
- Placenta Accreta, Third Trimester
- Keywords
- placenta accreta
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 4 Aug 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 10 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective:
To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta). To evaluate the diagnostic accuracy of the novel Ultrasound Scoring System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).
Secondary Objective:
- To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).
- To assess the relationship between the novel ultrasound score and postoperative complications, such as:
- Requirement for hysterectomy
- Bladder or bowel injury
- Blood transfusion requirement
- ICU admission rates
- To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
Detailed description
Primary Objective:
- To determine the optimal cutoff values of the ultrasound score for different PAS subtypes (no PAS, placenta accreta, placenta increta, and placenta percreta).
- To evaluate the diagnostic accuracy of the novel Ultrasound Scoring
- System in predicting the severity of Placenta Accreta Spectrum (PAS) (placenta accreta, increta, and percreta).
Secondary Objective:
- To correlate the novel ultrasound score with intraoperative findings (considered the gold standard) during cesarean delivery, including the degree of placental invasion and the need for surgical interventions (hysterectomy, bladder repair).
- To assess the relationship between the novel ultrasound score and postoperative complications, such as:
- Requirement for hysterectomy
- Bladder or bowel injury
- Blood transfusion requirement
- ICU admission rates
- To explore the potential for integrating the Ultrasound Scoring System with other clinical indicators (e.g., patient age, parity, and history of cesarean sections) to enhance the predictive accuracy for PAS.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Pregnant women aged 18 to 45 years. Gestational age ≥28 weeks at the time of enrollment. Diagnosed Placenta Previa with a history of: One or more previous cesarean sections Uterine scarring due to previous surgery as (myomectomy, D\&C, Metroplasty).
Key inclusion criteria (6 listed)
- Pregnant women aged 18 to 45 years.
- Gestational age ≥28 weeks at the time of enrollment.
- Diagnosed Placenta Previa with a history of:
- Singleton pregnancy.
Key exclusion criteria (4 listed)
- Women with multiple pregnancies (twins, triplets, etc.).
- Pregnancies complicated by acute medical conditions (e.g., heart failure, uncontrolled diabetes).
- Prior history of Blood diseases. (other than those related to pregnancy).
- Women who refuse to participate or withdraw consent during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
degree of placental invasion and inability to conserve the uterus
Time frame: 1 week
Need for Hysterectomy: Determined by the degree of placental invasion and inability to conserve the uterus \&Histopathogy confirmation. Bladder Injury: Recorded if any injury occurs during the procedure. Blood Transfusion Requirement: Amount of blood transfused intraoperatively. ICU Admission: Postoperative ICU admission requirement due to hemorrhage or other complications.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Placenta Accreta, Third Trimester
Not yet recruitingObservational study
Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies
Placenta Accreta, Third Trimester, Uterine Scar Dehiscence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Accreta, Third Trimester, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed Adel Khalifa, resident (01096679590, ahmedarsnl@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
degree of placental invasion and inability to conserve the uterus (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.